# Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer

> **NCT01563601** · PHASE3 · WITHDRAWN · sponsor: **Cephalon**

## Conditions studied

- Extensive-stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Obatoclax Mesylate, Carboplatine and Etoposide
- **DRUG:** Carboplatin and Etoposide

## Key facts

- **NCT ID:** NCT01563601
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-08
- **Primary completion:** 2016-05
- **Final completion:** 2018-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2012-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01563601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01563601, "Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01563601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*